CyTOF analysis of novel mucosal immune cells in Inflammatory bowel disease: relation with disease phenotype and location.

CyTOF analysis of novel mucosal immune cells in Inflammatory bowel disease: relation with disease phenotype and location. - CyTOF- IBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50535

Enrollment

220

Registered

2016-05-25

Start date

2016-05-12

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease. Chronic bowel disease

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age 10-40 years, with the following phenotype are to be included: with the following phenotype are to be included: - 50 control patients - 85 patients with ulcerative colitis - 85 patients with crohn's disease Within this group of 170 IBD patients (85 CD and UC patients) patients these patients will be included as well: Patiens age 18-40 years with L1 Crohn's disease with in the history an ileocecal resection and since operation naive for immunosuppessive medication. During endoscopy an active Crohn's diases is diagnosed. Patients age 18-40 years old with ulcerative colitis with in the past an ileoanal pouch procedure.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * No informed consent * Insufficient knowledge of Dutch language and/or inability to understand the information provided * Children aged between 12 and 18 years who are unable to understand the information provided. * If a patient or control suffer from other immune mediated diseases as well: rheumatoid artritis, psoriasis, hidradenitis suppurativa.

Design outcomes

Primary

Measure	Time frame
1. Characterisation of the cell populations associated with the different IBD fenotypes (CU or CD L1, L2, L3, L4). 2. Comprehensive phenotypic analysis and comparison of mucosal immune compartment in patients and controls ex vivo (year 1-3); 3.Comprehensive phenotypic analysis and comparison of mucosal stromal cell compartment in patients and controls ex vivo (year 1-3)	—

Secondary

Measure	Time frame
a. Comparison of immune and stromal cell compartments between pediatric and adult patients (year 1-3); b. Determination of correlates between changes in immune and stromal cell compartments and response to therapy (year 2 and 4); c. Comparison of the immune cell compartments between naïve patients and patients with active disease already on treatment to determinate the response on treatment. c. Functional analysis of selected immune and stromal cell subsets based on analysis in the endpoints above (year 3 and 4).	—

Measure

Time frame

a. Comparison of immune and stromal cell compartments between pediatric and adult patients (year 1-3); b. Determination of correlates between changes in immune and stromal cell compartments and response to therapy (year 2 and 4); c. Comparison of the immune cell compartments between naïve patients and patients with active disease already on treatment to determinate the response on treatment. c. Functional analysis of selected immune and stromal cell subsets based on analysis in the endpoints above (year 3 and 4).

—

Countries

Netherlands

Outcome results